BUZZ-Exact Sciences slumps after lowering full-year revenue forecast

Reuters11-07

BUZZ-Exact Sciences slumps after lowering full-year revenue forecast

** Cancer test maker Exact Sciences' EXAS.O shares down 24.9% at $53.72

** After market close on Tuesday, company lowered its 2024 total revenue and screening revenue forecast

** Company now sees its revenue forecast in the range of $2.73 bln to $2.75 bln vs prior estimate of $2.81 bln to $2.85 bln

** "The single biggest reason for why revenue would be down sequentially from Q3 to Q4 is the hurricanes." CFO Aaron Bloomer said in earnings call with analyst

** "Disruption from hurricane Helene and Milton negatively impacted Cologuard orders and results in September and October. Historically, about 18% of Cologuard tests are from patients who live in affected areas" Bloomer further said

** Cologuard is company's flagship product which provides at-home colon cancer screening test

** Company now expects its 2024 forecast for screening revenue to be in range of $2.08 bln and $2.10 bln compared with prior forecast of $2.16 bln to $2.18 bln

** At least 7 brokerages cut PTs on stock after results

**Including session's moves, stock down ~10.6% YTD

(Reporting by Prakhar Srivastava in Bengaluru)

((Prakhar.srivastava2@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481793409?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 02:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481793409","market":"us","top_or_hot":-1,"title":"BUZZ-Exact Sciences slumps after lowering full-year revenue forecast","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Exact Sciences slumps after lowering full-year revenue forecast </title></head><body><p>** Cancer test maker Exact Sciences' <span>EXAS.O</span> shares down 24.9% at $53.72</p><p>** After market close on Tuesday, company lowered its 2024 total revenue and screening revenue forecast</p><p>** Company now sees its revenue forecast in the range of $2.73 bln to $2.75 bln vs prior estimate of $2.81 bln to $2.85 bln</p><p>   ** \"The single biggest reason for why revenue would be down sequentially from Q3 to Q4 is the hurricanes.\" CFO Aaron Bloomer said in earnings call with analyst</p><p>   ** \"Disruption from hurricane Helene and Milton negatively impacted Cologuard orders and results in September and October. Historically, about 18% of Cologuard tests are from patients who live in affected areas\" Bloomer further said</p><p>   ** Cologuard is company's flagship product which provides at-home colon cancer screening test  </p><p>   ** Company now expects its 2024 forecast for screening revenue to be in range of $2.08 bln and $2.10 bln compared with prior forecast of $2.16 bln to $2.18 bln</p><p>   ** At least 7 brokerages cut PTs on stock after results</p><p>   **<span>Including session's moves</span>, stock down ~10.6% YTD</p><p> (Reporting by Prakhar Srivastava in Bengaluru)</p><p> ((Prakhar.srivastava2@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Exact Sciences slumps after lowering full-year revenue forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Exact Sciences slumps after lowering full-year revenue forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 02:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nL4N3MD32A:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-Exact Sciences slumps after lowering full-year revenue forecast ** Cancer test maker Exact Sciences' EXAS.O shares down 24.9% at $53.72** After market close on Tuesday, company lowered its 2024 ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nL4N3MD32A:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXAS","symbol_name":"精密科学","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nL4N3MD32A:1","article_id":"2481793409","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481793409","pubTimestamp":1730918559,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Exact Sciences slumps after lowering full-year revenue forecast ** Cancer test maker Exact Sciences' EXAS.O shares down 24.9% at $53.72** After market close on Tuesday, company lowered its 2024 t","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EXAS":"精密科学"},"translate_title":"BUZZ-Exact Sciences下调全年收入预测后股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":0.9},"content_text":"BUZZ-Exact Sciences slumps after lowering full-year revenue forecast ** Cancer test maker Exact Sciences' EXAS.O shares down 24.9% at $53.72** After market close on Tuesday, company lowered its 2024 total revenue and screening revenue forecast** Company now sees its revenue forecast in the range of $2.73 bln to $2.75 bln vs prior estimate of $2.81 bln to $2.85 bln   ** \"The single biggest reason for why revenue would be down sequentially from Q3 to Q4 is the hurricanes.\" CFO Aaron Bloomer said in earnings call with analyst   ** \"Disruption from hurricane Helene and Milton negatively impacted Cologuard orders and results in September and October. Historically, about 18% of Cologuard tests are from patients who live in affected areas\" Bloomer further said   ** Cologuard is company's flagship product which provides at-home colon cancer screening test     ** Company now expects its 2024 forecast for screening revenue to be in range of $2.08 bln and $2.10 bln compared with prior forecast of $2.16 bln to $2.18 bln   ** At least 7 brokerages cut PTs on stock after results   **Including session's moves, stock down ~10.6% YTD (Reporting by Prakhar Srivastava in Bengaluru) ((Prakhar.srivastava2@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481793409"}